

KFIN/GXP/SEP/2022
April 06, 2022

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals
Limited Dr. Annie Besant Road
Worli, Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended March 31,2022.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended March 31, 2022.

Description of Complaint	Opening Balance as on 01.01.2022	Received during the Period 01.01.2022 to 31.03.2022	Attended/Resolved during the Period 01.01.2022 to 31.03.2022	Pending as on 31.03.2022
Non-receipt of Dividend	NIL	11	11	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of share certificates	NIL	01	01	NIL
SEBI	NIL	02	02	NIL
Stock Exchange	01	04	05	NIL
Total	01	18	19	NIL

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Private Limited



Rajitha Cholleti